Predicate |
Object |
assignee |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_f7ddc4774cf5f8a0bda44a780d73c53d |
classificationCPCAdditional |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K2319-30 |
classificationCPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K47-6849 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K47-6811 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K14-62 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K38-28 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K17-08 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K47-68 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P3-10 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K47-6889 |
classificationIPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P3-10 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K38-28 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07K14-62 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07K17-08 |
filingDate |
2015-08-18-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
inventor |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_7ceba070752048340ff9a5b6d9aadd3d http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_575aa99b4a1b3d36d114015551396525 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_73a8d4cc16357235942e34e3fda3ffb9 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_aaaa024eec59427699acaa88023d52fc http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_aa94e4debd1ff1fff49b15bbdfffa5ce http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_fc15401a6b2dff5b235f2f79e18fbb24 |
publicationDate |
2015-12-07-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
publicationNumber |
PH-12015501815-B1 |
titleOfInvention |
Site-specific insulin conjugate |
abstract |
Provided are an insulin conjugate having improved insulin receptor binding affinity and increased activity, in which a non-peptidyl polymer and an immunoglobulin Fc region are site-specifically linked to an amino acid residue of the insulin beta chain excluding the N-terminus thereof via a covalent bond, a long-acting formulation including the same, and a preparation method thereof. The insulin conjugate of the present invention is used to provide an insulin formulation which exhibits a remarkably increased in vivo activity of the peptide. |
priorityDate |
2013-02-26-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
type |
http://data.epo.org/linked-data/def/patent/Publication |